Plecanatide: Completed Phase III enrollment

Synergy completed enrollment of about 1,350 patients in a double-blind, placebo-controlled, U.S. Phase III trial evaluating 3 and 6 mg oral plecanatide once daily for 12 weeks. Data from the trial are...